| http://dbpedia.org/ontology/abstract
|
موكسيتوموماب باسودوتوكس هو جسم مضاد وحيد ا … موكسيتوموماب باسودوتوكس هو جسم مضاد وحيد النسيلة تطوره التابعة ، حصل على ملف دواء تجريبي جديد لتجربته في علاج بعض أنواع الأورام مثل أورام الدم مثل اللمفومة لاهودجكينية وابيضاض الدم الليمفاوي المزمن وابيضاض الدم الليمفاوي الحاد عند الأطفال وابيضاض الخلية المشعرة. بدأت المرحلة الثالثة من تجاربه السريرية في 16 أيار 2013.لثالثة من تجاربه السريرية في 16 أيار 2013.
, Moxetumomab pasudotox, sold under the bran … Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL. The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38. This toxin is a 38 kDa fragment of Pseudomonas exotoxin A. Hairy cell leukemia (HCL) is a rare, slow-growing cancer of the blood in which the bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. HCL is named after these extra B cells which look “hairy” when viewed under a microscope. As the number of leukemia cells increases, fewer healthy white blood cells, red blood cells and platelets are produced.ed blood cells and platelets are produced.
, Моксетумомаб пасудотокс — конъюгат антитело-препарат для лечения . Одобрен для применения: США (2018).
, Moxetumomab Pasudotox is een experimenteel … Moxetumomab Pasudotox is een experimenteel (fase 3)-medicijn voor de behandeling van haarcelleukemie en acute lymfatische leukemie. Het is een monoclonaal antilichaam dat zich richt op , een molecuul aan het oppervlak van afwijkende B-cellen. Moxetumomab Pasudotox bindt zich aan CD22, gaat de cel binnen en laat een toxine los, dat de cel doodt. en laat een toxine los, dat de cel doodt.
|
| http://dbpedia.org/ontology/alternativeName
|
Lumoxiti
|
| http://dbpedia.org/ontology/casNumber
|
1020748-57-5
|
| http://dbpedia.org/ontology/drugbank
|
DB12688
|
| http://dbpedia.org/ontology/fdaUniiCode
|
2NDX4B6N8F
|
| http://dbpedia.org/ontology/kegg
|
D09932
|
| http://dbpedia.org/ontology/medlinePlus
|
a618052
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://www.cancer.gov/about-cancer/treatment/drugs/moxetumomabpasudotoxtdfk +
, https://www.cancer.gov/publications/dictionaries/cancer-drug +
, https://druginfo.nlm.nih.gov/drugportal/name/moxetumomab%20pasudotox +
|
| http://dbpedia.org/ontology/wikiPageID
|
33024077
|
| http://dbpedia.org/ontology/wikiPageLength
|
17876
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1090379296
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Cambridge_Antibody_Technology +
, http://dbpedia.org/resource/Capillary_leak_syndrome +
, http://dbpedia.org/resource/Immunotoxin +
, http://dbpedia.org/resource/National_Cancer_Institute +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies_for_tumors +
, http://dbpedia.org/resource/Hairy_cell_leukemia +
, http://dbpedia.org/resource/Committee_for_Medicinal_Products_for_Human_Use +
, http://dbpedia.org/resource/Category:AstraZeneca_brands +
, http://dbpedia.org/resource/Acute_lymphoblastic_leukemia +
, http://dbpedia.org/resource/Fast_track_%28FDA%29 +
, http://dbpedia.org/resource/Intravenous_therapy +
, http://dbpedia.org/resource/European_Medicines_Agency +
, http://dbpedia.org/resource/Category:Orphan_drugs +
, http://dbpedia.org/resource/Anti-CD22_immunotoxin +
, http://dbpedia.org/resource/Hematological_malignancies +
, http://dbpedia.org/resource/AstraZeneca +
, http://dbpedia.org/resource/B_cells +
, http://dbpedia.org/resource/Non-Hodgkin_lymphoma +
, http://dbpedia.org/resource/Priority_review +
, http://dbpedia.org/resource/Orphan_drug +
, http://dbpedia.org/resource/Cooperative_Research_and_Development_Agreement +
, http://dbpedia.org/resource/CD22 +
, http://dbpedia.org/resource/Genencor +
, http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/Pseudomonas_exotoxin +
, http://dbpedia.org/resource/Category:Withdrawn_drugs +
, http://dbpedia.org/resource/Danisco +
, http://dbpedia.org/resource/National_Institutes_of_Health +
, http://dbpedia.org/resource/Chronic_lymphocytic_leukemia +
, http://dbpedia.org/resource/Investigational_New_Drug +
, http://dbpedia.org/resource/Category:Antibody-drug_conjugates +
, http://dbpedia.org/resource/Food_and_Drug_Administration +
|
| http://dbpedia.org/property/atcPrefix
|
L01
|
| http://dbpedia.org/property/atcSuffix
|
FB02
|
| http://dbpedia.org/property/c
|
2804
|
| http://dbpedia.org/property/casNumber
|
1020748
|
| http://dbpedia.org/property/chemspiderid
|
none
|
| http://dbpedia.org/property/dailymedid
|
Moxetumomab_pasudotox
|
| http://dbpedia.org/property/drugbank
|
DB12688
|
| http://dbpedia.org/property/h
|
4339
|
| http://dbpedia.org/property/kegg
|
D09932
|
| http://dbpedia.org/property/legalEu
|
Rx-only
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/licenceEu
|
yes
|
| http://dbpedia.org/property/mabType
|
mab
|
| http://dbpedia.org/property/medlineplus
|
a618052
|
| http://dbpedia.org/property/n
|
783
|
| http://dbpedia.org/property/o
|
870
|
| http://dbpedia.org/property/pregnancyCategory
|
Contraindicated
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Intravenous_therapy +
|
| http://dbpedia.org/property/s
|
14
|
| http://dbpedia.org/property/source
|
o
|
| http://dbpedia.org/property/synonyms
|
moxetumomab pasudotox-tdfk, CAT-8015
|
| http://dbpedia.org/property/target
|
http://dbpedia.org/resource/CD22 +
|
| http://dbpedia.org/property/tradename
|
Lumoxiti
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
2
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
458284291
|
| http://dbpedia.org/property/watchedfields
|
changed
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Infobox_drug +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:Use_dmy_dates +
, http://dbpedia.org/resource/Template:Drugs.com +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Monoclonals_for_tumors +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Antibody-drug_conjugates +
, http://dbpedia.org/resource/Category:Withdrawn_drugs +
, http://dbpedia.org/resource/Category:Orphan_drugs +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies_for_tumors +
, http://dbpedia.org/resource/Category:AstraZeneca_brands +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Antibody +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Moxetumomab_pasudotox?oldid=1090379296&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Moxetumomab_pasudotox +
|
| owl:sameAs |
http://rdf.freebase.com/ns/m.03d2h4h +
, http://dbpedia.org/resource/Moxetumomab_pasudotox +
, http://ar.dbpedia.org/resource/%D9%85%D9%88%D9%83%D8%B3%D9%8A%D8%AA%D9%88%D9%85%D9%88%D9%85%D8%A7%D8%A8_%D8%A8%D8%A7%D8%B3%D9%88%D8%AF%D9%88%D8%AA%D9%88%D9%83%D8%B3 +
, http://ru.dbpedia.org/resource/%D0%9C%D0%BE%D0%BA%D1%81%D0%B5%D1%82%D1%83%D0%BC%D0%BE%D0%BC%D0%B0%D0%B1_%D0%BF%D0%B0%D1%81%D1%83%D0%B4%D0%BE%D1%82%D0%BE%D0%BA%D1%81 +
, http://nl.dbpedia.org/resource/Moxetumomab_Pasudotox +
, http://rdf.freebase.com/ns/m.0h55gtx +
, http://www.wikidata.org/entity/Q14605217 +
, http://yago-knowledge.org/resource/Moxetumomab_pasudotox +
, https://global.dbpedia.org/id/TMEm +
|
| rdf:type |
http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/ontology/MonoclonalAntibody +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/MonoclonalAntibody115029781 +
, http://dbpedia.org/class/yago/WikicatMonoclonalAntibodies +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/Antibody115027189 +
, http://dbpedia.org/class/yago/Part113809207 +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/class/yago/Macromolecule114944888 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/Protein114728724 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Thing100002452 +
, http://dbpedia.org/class/yago/Molecule114682133 +
, http://dbpedia.org/class/yago/Unit109465459 +
|
| rdfs:comment |
Моксетумомаб пасудотокс — конъюгат антитело-препарат для лечения . Одобрен для применения: США (2018).
, Moxetumomab pasudotox, sold under the bran … Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL. The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38. This toxin is a 38 kDa fragment of Pseudomonas exotoxin A.38 kDa fragment of Pseudomonas exotoxin A.
, موكسيتوموماب باسودوتوكس هو جسم مضاد وحيد ا … موكسيتوموماب باسودوتوكس هو جسم مضاد وحيد النسيلة تطوره التابعة ، حصل على ملف دواء تجريبي جديد لتجربته في علاج بعض أنواع الأورام مثل أورام الدم مثل اللمفومة لاهودجكينية وابيضاض الدم الليمفاوي المزمن وابيضاض الدم الليمفاوي الحاد عند الأطفال وابيضاض الخلية المشعرة. بدأت المرحلة الثالثة من تجاربه السريرية في 16 أيار 2013.لثالثة من تجاربه السريرية في 16 أيار 2013.
, Moxetumomab Pasudotox is een experimenteel … Moxetumomab Pasudotox is een experimenteel (fase 3)-medicijn voor de behandeling van haarcelleukemie en acute lymfatische leukemie. Het is een monoclonaal antilichaam dat zich richt op , een molecuul aan het oppervlak van afwijkende B-cellen. Moxetumomab Pasudotox bindt zich aan CD22, gaat de cel binnen en laat een toxine los, dat de cel doodt. en laat een toxine los, dat de cel doodt.
|
| rdfs:label |
Moxetumomab pasudotox
, Moxetumomab Pasudotox
, Моксетумомаб пасудотокс
, موكسيتوموماب باسودوتوكس
|
